A Clinical study of 1/10-vial Histaglobin nebulizer therapy for nasal allergy

Abstract

The effect of a smaller dosage of Histaglobin nebulizer (1/10 vial) was examined in 13 patients suffering from perenial allergic rhinitis patients. The patients were treated twice a week for four weeks with a nebulizer of Histaglobin. Within one week of the treatment, the patients showed improvement which continued in 12 of the 13 patients for four weeks of treatment. The effect lasted for about a week or more after the treatment was stopped. Histaglobin nebulizer is as effective at a dose of 1/10 as at other doses of 1/4 or 1/2 vial.